Download MendeleyExploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib.
Windsor, M.A., Valk, P.L., Xu, S., Banerjee, S., Marnett, L.J.(2013) Bioorg Med Chem Lett 23: 5860-5864
- PubMed: 24060487
- DOI: https://doi.org/10.1016/j.bmcl.2013.08.097
- Primary Citation of Related Structures:
4OTY - PubMed Abstract:
Lumiracoxib is a substrate-selective inhibitor of endocannabinoid oxygenation by cyclooxygenase-2 (COX-2). We assayed a series of lumiracoxib derivatives to identify the structural determinants of substrate-selective inhibition. The hydrogen-bonding potential of the substituents at the ortho positions of the aniline ring dictated the potency and substrate selectivity of the inhibitors. The presence of a 5'-methyl group on the phenylacetic acid ring increased the potency of molecules with a single ortho substituent. Des-fluorolumiracoxib (2) was the most potent and selective inhibitor of endocannabinoid oxygenation. The positioning of critical substituents in the binding site was identified from a 2.35Å crystal structure of lumiracoxib bound to COX-2.
Organizational Affiliation:
A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Department of Biochemistry, Department of Chemistry, Department of Pharmacology, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, United States.
